Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Suny Upstate Medical University

Neither a doctor nor a teaching hospital

Research payments

$2,015,913

264 payments

Through program year 2025, Suny Upstate Medical University is reported as receiving $2,015,913 in research payments, across 264 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $144,805 9
2024 Research $146,971 11
2023 Research $188,161 28
2022 Research $353,233 30
2021 Research $374,057 51
2020 Research $299,949 86
2019 Research $508,736 49

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $470,054 21 payments
  2. Merck Sharp & Dohme Corporation $421,134 107 payments
  3. Medtronic MiniMed, Inc. $307,346 2 payments
  4. Celgene Corporation $152,717 3 payments
  5. Jazz Pharmaceuticals Inc. $147,750 4 payments
  6. E.R. Squibb & Sons, L.L.C. $142,458 10 payments
  7. Amgen Inc. $96,495 9 payments
  8. Novartis Pharmaceuticals Corporation $79,573 1 payment
  9. Helsinn Healthcare SA $51,250 7 payments
  10. Biogen, Inc. $35,016 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma R,M HNSCC LEAP-010 $323,365 11 payments
  2. CEP 304 670G Outcomes Study $307,346 2 payments
  3. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cc-220 in Subjects With Active Systemic Lupus Erythematosus (Cc-220-Sle-002) $152,705 2 payments
  4. A Phase 3 Randomized Trial for Patients With de Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin Go to Cpx351 With Go $138,750 1 payment
  5. A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy $134,319 3 payments
  6. A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis $83,808 2 payments
  7. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation $83,478 4 payments
  8. A Randomized, Open-Label, Phase II Study of Canakinumab Or Pembrolizumab As Monotherapy Or in Combination As Neoadjuvant Therapy in Subjects With Resectable Non-Small Cell Lung Cancer (Canopy-N) $79,573 1 payment
  9. A Study Evaluating the Long-term Safety of VX-445 Combination Therapy $77,466 4 payments
  10. A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma $54,243 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record